Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 **Form SA1743** July 2024

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Eltrombopag				
Initial application — idiopathic thrombocytope Applications only from a haematologist. Approval Prerequisites(tick boxes where appropriate)				
Patient has had a splenectomy				
Two immunosuppressive therapies have been trialled and failed after therapy of 3 months each (or 1 month for rituximab)				
Patient has a platelet count of 20,000 to 30,000 platelets per microlitre and has evidence of significant mucocutaneous bleeding				
Patient has a platelet count of less than or equal to 20,000 platelets per microlitre and has evidence of active bleeding				
Patient has a platelet count	of less than or equal to 10,000 platelets per microlitre			
Initial application — idiopathic thrombocytopenic purpura - preparation for splenectomy Applications only from a haematologist. Approvals valid for 6 weeks.  Prerequisites(tick box where appropriate)  The patient requires eltrombopag treatment as preparation for splenectomy				
Initial application — idiopathic thrombocytope Applications only from a haematologist. Approval Prerequisites(tick boxes where appropriate)				
<del>_</del>	documented contraindication to splenectomy for clinic	al reasons		
Two immunosuppressive therapie	s have been trialled and failed after therapy of 3 mont	hs each (or 1 month for rituximab)		
	ocytopenic purpura* with a platelet count of less than	or equal to 20,000 platelets per microliter		
	pocytopenic purpura* with a platelet count of 20,000 to	30,000 platelets per microlitre and significant		
Initial application				
Initial application — severe aplastic anaemia Applications only from a haematologist. Approvals valid for 3 months.				
Prerequisites(tick boxes where appropriate)				
Two immunosuppressive therapie	s have been trialled and failed after therapy of at least	t 3 months duration		
	anaemia with a platelet count of less than or equal to	20,000 platelets per microliter		
	anaemia with a platelet count of 20,000 to 30,000 plat	elets per microlitre and significant mucocutaneous		

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 **Form SA1743** July 2024

APPL	CANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg N	0:	First Names:	First Names:	
Name		Surname:	Surname:	
Addre	SS:	DOB:	Address:	
		Address:		
	umber:mbopag - continued		Fax Number:	
Renewal — idiopathic thrombocytopenic purpura - post-splenectomy  Current approval Number (if known):				
Applications only from a haematologist. Approvals valid for 12 months.  Prerequisites(tick box where appropriate)				
The patient has obtained a response (see Note) from treatment during the initial approval or subsequent renewal periods and further treatment is required  Note: Response to treatment is defined as a platelet count of > 30,000 platelets per microlitre.				
Rene	wal — idiopathic thrombocytopenic purpu	ra contraindicated to splenectomy		
Current approval Number (if known):				
Applications only from a haematologist. Approvals valid for 12 months.  Prerequisites(tick boxes where appropriate)				
	The patient's significant contraindic	cation to splenectomy remains		
	The patient has obtained a response from treatment during the initial approval period and			
	Patient has maintained a platelet count of at least 50,000 platelets per microlitre on treatment			
	Further treatment with eltrombopa	g is required to maintain response		
Renewal — severe aplastic anaemia				
Curre	nt approval Number (if known):			
	cations only from a haematologist. Approvals equisites(tick boxes where appropriate)	valid for 12 months.		
	The patient has obtained a respon- period	se from treatment of at least 20,000 platelets per mic	rolitre above baseline during the initial approval	
		for a minimum of 8 weeks during the initial approval	period	

I confirm the above details are correct and that in signing this form I understand I may be audited.